Logo
x

Search

Subscribe Now

wet age-related macular degeneration

Polpharma Biologics Reports the US FDA's Acceptance of BQ201's (biosimilar- ranibizumab) BLA for Review to Treat Wet Age-Related Macular Degeneration

Polpharma Biologics Reports the US FDA's Acceptance of BQ201's (biosimilar- ranibizumab) BLA for Review to Treat Wet Age-Related M...

  • October 5, 2021
Henlius Reports First Patient Dosing in P-I Study of HLX04-O (biosimilar- bevacizumab) for Wet Age-Related Macular Degeneration

Henlius Reports First Patient Dosing in P-I Study of HLX04-O (biosimilar- bevacizumab) for Wet Age-Related Macular Degeneration

  • July 19, 2021
Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration

Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration

  • May 31, 2021
Xbrane Reports Patient Enrollment Completion in P-lll XPLORE Study of Xlucane (biosimilar- ranibizumab)

Xbrane Reports Patient Enrollment Completion in P-lll XPLORE Study of Xlucane (biosimilar- ranibizumab)

  • November 11, 2020
Novartis Reports Results of Beovu (brolucizumab) in Two New Post-Hoc Analyses of P-III HAWK and HARRIER Studies for Wet AMD

Novartis Reports Results of Beovu (brolucizumab) in Two New Post-Hoc Analyses of P-III HAWK and HARRIER Studies for Wet AMD

  • October 6, 2020
Novartis' Beovu (brolucizumab) Receives FDA's Approval for the Treatment of Wet Age-Related Macular Degeneration

Novartis' Beovu (brolucizumab) Receives FDA's Approval for the Treatment of Wet Age-Related Macular Degeneration

  • October 8, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.